CNS demyelination and quadrivalent HPV vaccination
- 1 January 2009
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (1) , 116-119
- https://doi.org/10.1177/1352458508096868
Abstract
Vaccination is generally considered safe in patients with multiple sclerosis (MS). We report five patients who presented with multifocal or atypical demyelinating syndromes within 21 days of immunization with the quadrivalent human papilloma virus (HPV) vaccine, Gardasil®. Although the target population for vaccination, young females, has an inherently high risk for MS, the temporal association with demyelinating events in these cases may be explained by the potent immuno-stimulatory properties of HPV virus-like particles which comprise the vaccine. A prospective case–control study of patients with MS or clinically isolated demyelinating syndromes receiving the Gardasil® vaccine may provide relevant safety data in this population.Keywords
This publication has 8 references indexed in Scilit:
- Hepatitis B Vaccination and the Risk of Childhood-Onset Multiple SclerosisArchives of Pediatrics & Adolescent Medicine, 2007
- Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case–control study using the self-controlled case series methodVaccine, 2007
- Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004Vaccine, 2007
- Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year studyPublished by Elsevier ,2003
- Hepatitis B Vaccination and First Central Nervous System Demyelinating Event: A Case-Control StudyNeuroepidemiology, 2002
- Papillomavirus-Like Particles Induce Acute Activation of Dendritic CellsThe Journal of Immunology, 2001
- A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosisNeurology, 1997
- CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSISThe Lancet, 1985